Acelyrin Inc (SLRN)

Dec 19, 2024

Fmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 19, 2024

Dec 19, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Fmr LLC - MarketBeat

Dec 19, 2024

Dec 15, 2024

Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Dec 15, 2024

Dec 14, 2024

SLRN stock touches 52-week low at $3.18 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 13, 2024

Acelyrin (NASDAQ:SLRN) Earns “Neutral” Rating from HC Wainwright - Defense World

Dec 13, 2024

Dec 12, 2024

Acelyrin stock drops as izokibep trial fails to meet primary endpoint - MSN

Dec 12, 2024

Dec 11, 2024

Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data - BioSpace

Dec 11, 2024

Dec 11, 2024

Acelyrin's (SLRN) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 11, 2024

Dec 11, 2024

Acelyrin shares retain neutral rating despite trial setback By Investing.com - Investing.com UK

Dec 11, 2024

Dec 11, 2024

Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks

Dec 11, 2024

Dec 11, 2024

Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 11, 2024

Dec 11, 2024

Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha

Dec 11, 2024

Dec 10, 2024

Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch

Dec 10, 2024

Dec 10, 2024

Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch

Dec 10, 2024

Dec 10, 2024

Acelyrin announces izokibep trial did not meet primary endpoint - TipRanks

Dec 10, 2024

Dec 10, 2024

ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks

Dec 10, 2024

Dec 10, 2024

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times

Dec 10, 2024

Dec 09, 2024

Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha

Dec 09, 2024

Dec 07, 2024

Polar Asset Management Partners Inc. Sells 150,700 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 07, 2024

Dec 06, 2024

Jacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Dec 06, 2024

Nov 28, 2024

Acuta Capital Partners LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat

Nov 28, 2024

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Nov 22, 2024

Nov 22, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Analysts - MarketBeat

Nov 22, 2024

Nov 18, 2024

HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat

Nov 18, 2024

Nov 15, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada

Nov 15, 2024

Nov 15, 2024

Acelyrin discloses ValenzaBio acquisition financials - Investing.com India

Nov 15, 2024

Nov 14, 2024

TD Cowen maintains Buy rating on Acelyrin shares - Investing.com

Nov 14, 2024

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com

Nov 14, 2024

Nov 14, 2024

Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

ACELYRIN, INC. Advances Key Drug Developments - TipRanks

Nov 13, 2024

Nov 13, 2024

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times

Nov 13, 2024

Nov 13, 2024

ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan

Nov 13, 2024

Nov 08, 2024

(SLRN) Investment Analysis and Advice - Stock Traders Daily

Nov 08, 2024

Nov 07, 2024

Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat

Nov 07, 2024

Nov 07, 2024

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times

Nov 07, 2024

Nov 06, 2024

ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com

Nov 05, 2024

Oct 30, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 30, 2024

Oct 28, 2024

(SLRN) Proactive Strategies - Stock Traders Daily

Oct 28, 2024

Oct 28, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat

Oct 28, 2024

Oct 27, 2024

Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat

Oct 27, 2024

Oct 20, 2024

The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World

Oct 20, 2024

Oct 18, 2024

Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat

Oct 18, 2024

Oct 18, 2024

(SLRN) Trading Advice - Stock Traders Daily

Oct 18, 2024

Oct 17, 2024

Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat

Oct 17, 2024

Oct 17, 2024

SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan

Oct 17, 2024

Oct 16, 2024

Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat

Oct 16, 2024

Oct 16, 2024

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times

Oct 16, 2024